These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

946 related items for PubMed ID: 23428009

  • 1. High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study.
    Leoncini M, Toso A, Maioli M, Angiolillo DJ, Giusti B, Marcucci R, Abbate R, Bellandi F.
    JACC Cardiovasc Interv; 2013 Feb; 6(2):169-79. PubMed ID: 23428009
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial.
    Reed GW, Cannon CP, Waalen J, Teirstein PS, Tanguay JF, Berger PB, Angiolillo DJ, Price MJ.
    Catheter Cardiovasc Interv; 2017 Feb 01; 89(2):190-198. PubMed ID: 26909669
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of CYP2C19 Polymorphisms on the Platelet Response to Clopidogrel and Influence on the Effect of High Versus Standard Dose Clopidogrel in Carotid Artery Stenting.
    González A, Moniche F, Cayuela A, García-Lozano JR, Torrecillas F, Escudero-Martínez I, Gonzalez-Marcos JR, Mayol A, Montaner J.
    Eur J Vasc Endovasc Surg; 2016 Feb 01; 51(2):175-86. PubMed ID: 26526111
    [Abstract] [Full Text] [Related]

  • 9. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study.
    Mangiacapra F, Patti G, Barbato E, Peace AJ, Ricottini E, Vizzi V, Gatto L, D'Ambrosio A, De Bruyne B, Wijns W, Di Sciascio G.
    JACC Cardiovasc Interv; 2012 Mar 01; 5(3):281-9. PubMed ID: 22440493
    [Abstract] [Full Text] [Related]

  • 10. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in Japanese patients with stable coronary artery disease.
    Nishi T, Ariyoshi N, Nakayama T, Fujimoto Y, Sugimoto K, Takahara M, Wakabayashi S, Koshizaka M, Hanaoka H, Kobayashi Y.
    Circ J; 2015 Mar 01; 79(11):2439-44. PubMed ID: 26310876
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping.
    Alexopoulos D, Dimitropoulos G, Davlouros P, Xanthopoulou I, Kassimis G, Stavrou EF, Hahalis G, Athanassiadou A.
    JACC Cardiovasc Interv; 2011 Apr 01; 4(4):403-10. PubMed ID: 21511219
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Platelet activity measured by a rapid turnaround assay identifies coronary artery bypass grafting patients at increased risk for bleeding and transfusion complications after clopidogrel administration.
    Rosengart TK, Romeiser JL, White LJ, Fratello A, Fallon E, Senzel L, Shroyer AL.
    J Thorac Cardiovasc Surg; 2013 Nov 01; 146(5):1259-1266, 1266.e1; discussion 1266. PubMed ID: 23953984
    [Abstract] [Full Text] [Related]

  • 15. Impact of initial clinical presentation on clopidogrel low response.
    Landel JB, Bauters A, Delhaye C, Bonello L, Sudre A, Susen S, Bauters C, Lablanche JM, Lemesle G.
    Arch Cardiovasc Dis; 2013 Nov 01; 106(11):593-600. PubMed ID: 24070598
    [Abstract] [Full Text] [Related]

  • 16. P2Y12 Inhibition in Patients Requiring Oral Anticoagulation After Percutaneous Coronary Intervention: The SWAP-AC-2 Study.
    Ortega-Paz L, Bor W, Franchi F, van den Broek WWA, Rollini F, Giordano S, Galli M, Been L, Ghanem G, Shalhoub A, Garabedian H, Al Saleh T, Uzunoglu E, Zhou X, Rivas A, Pineda AM, Suryadevara S, Soffer D, Mahowald MK, Choi CY, Zenni MM, Phoenix F, Ajjan RA, Ten Berg JM, Angiolillo DJ.
    JACC Cardiovasc Interv; 2024 Jun 10; 17(11):1356-1370. PubMed ID: 38597172
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
    Legrand V, Cuisset T, Chenu P, Vrolix M, Martinez C, Dens J, Gach O, Boland J, Claeys MJ, Magne J, Barbato E, Wijns W.
    EuroIntervention; 2014 Jun 10; 10(2):204-11. PubMed ID: 24952058
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.